The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,318.00
Bid: 12,288.00
Ask: 12,292.00
Change: -52.00 (-0.42%)
Spread: 4.00 (0.033%)
Open: 12,326.00
High: 12,428.00
Low: 12,260.00
Prev. Close: 12,370.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-German COVID-19 cases are growing exponentially again -RKI

Tue, 16th Mar 2021 06:36

* Epidemiologist says 'irrational' to loosen restrictions

* Merkel, state leaders allowed phased easing of curbs

* City of Berlin puts on hold plans for further easing
(Adds Berlin stopping further easing of lockdown)

BERLIN, March 16 (Reuters) - Coronavirus infections are
rising exponentially in Germany, an expert at the Robert Koch
Institute for infectious diseases said on Tuesday, putting at
risk plans to lift the lockdown and revive the economy.

The number of cases per 100,000 reported on Tuesday was
83.7, up from 68 a week ago, and the RKI has said that metric
could reach 200 by the middle of next month.

Germany is definitely in a third wave of the pandemic,
driven by the fact it has loosened restrictions in recent weeks
just as a more transmissable variant has spread, Dirk Brockmann,
an epidemiologist at the RKI, told Germany's ARD television.

"It has been totally irrational to loosen up here. It is
just fuelling this exponential growth," he said.

Chancellor Angela Merkel and state leaders agreed a phased
easing of curbs earlier this month along with an "emergency
brake" to let authorities reimpose restrictions if case numbers
rise above 100 per 100,000 on three consecutive days.

They are due to meet again on March 22 to discuss whether to
allow any further relaxation of the rules.

The state government in the city of Berlin decided on
Tuesday to put on hold any more easing, such as allowing
restaurants or cinemas to open, the Tagesspiegel newspaper
reported.

VACCINATION WOES

Germany's decision on Monday to suspend AstraZeneca's
vaccine could delay progress in reaching herd immunity
and postpone an economic recovery in the second quarter,
analysts said.

The decision follows seven cases of thrombosis in Germany,
including three deaths, and delivers a major setback to the
country's drive to speed up its sluggish vaccination campaign.

A planned meeting between Merkel and state leaders on
Wednesday to discuss using family doctors to administer COVID-19
vaccines has been postponed until after the European Medicines
Agency completes its review into the AstraZeneca shot.

AstraZeneca has said an analysis of its safety data covering
reported cases from over 17 million vaccine doses given had
shown no evidence of an increased risk of pulmonary embolism,
deep vein thrombosis or low levels of platelets.

The RKI's Brockmann noted that 1,000 people in a million had
died of COVID-19, compared to possibly 1 in a million from
complications associated with the vaccine.

"In the risk groups, the risk of dying of COVID is much,
much higher. That means it is probably 100,000 times more likely
to die of COVID than because of an AstraZeneca vaccine," he
said.
(Reporting by Emma Thomasson and Caroline Copley, Editing by
Timothy Heritage and Gareth Jones)

More News
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.